Zhi Ye

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 4

Top Topics

Amyotrophic Lateral Sclerosis

Rheumatoid Arthritis

Top Venues

Drug design, development and therapy

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Signal transduction and targeted therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaoyan He, Min Li, Zhi Ye, Xiaoling You, Jia Wang, Xin Xiao, Guofeng Zhu, Jun Wei, Yunhong Zha
Identification of Piperlongumine as Potent Inhibitor of Necroptosis. Drug design, development and therapy 17 (2023)
Jun Wei, Min Li, Zhi Ye, Xinqian Hu, Xiaoyan He, Jia Wang, Gaofeng Chen, Chengyu Zou, Daichao Xu, Hongbing Zhang, Junying Yuan, Yunhong Zha
Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis. Signal transduction and targeted therapy 8 (1) (2023)
Xiaoyan He, Min Li, Zhi Ye, Xiaoling You, Jia Wang, Xin Xiao, Guofeng Zhu, Jun Wei, Yunhong Zha
Identification of Piperlongumine as Potent Inhibitor of Necroptosis. Drug design, development and therapy 17 (2023)
Min Li, Jun Wei, Guofeng Zhu, Shufang Fu, Xiaoyan He, Xinqian Hu, Yajie Yu, Yan Mou, Jia Wang, Xiaoling You, Xin Xiao, Tanrong Gu, Zhi Ye, Yunhong Zha
Quizartinib inhibits necroptosis by targeting receptor-interacting serine/threonine protein kinase 1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 37 (10) (2023)